Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch) (AC120-8231)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00793156
Recruitment Status : Unknown
Verified February 2010 by Acologix, Inc..
Recruitment status was:  Not yet recruiting
First Posted : November 19, 2008
Last Update Posted : February 4, 2010
Information provided by:
Acologix, Inc.

Brief Summary:
Primary objective of this multicenter, double-blind, placebo controlled, randomized withdrawal study are to determine the effectiveness and safety of orally administered AC-820 in doses of 2.5 µg and 5.0 µg daily in patients with moderate to severe itching associated with end-stage renal disease and hemodialysis, and perform a population PK analysis.

Condition or disease Intervention/treatment Phase
Uremic Pruritus Drug: Nalfurafine HCl 2.5 µg Drug: Nalfurafine HCl 5.0 µg Other: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 350 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized-Withdrawal Phase 3 Study Evaluation the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)
Study Start Date : December 2009
Estimated Primary Completion Date : December 2010
Estimated Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Itching

Arm Intervention/treatment
Placebo Comparator: Placebo
Patients will be randomized into Placebo group
Other: Placebo
Placebo daily dose

Active Comparator: 2
2.5 µg group randomized
Drug: Nalfurafine HCl 2.5 µg
Daily dose of 2.5 µg

Active Comparator: 3
5.0 µg group randomized
Drug: Nalfurafine HCl 5.0 µg
Daily dose of 5.0 µg

Primary Outcome Measures :
  1. Primary efficacy endpoint is the change in worst itching intensity from baseline, compared to that in the last two weeks of the double blind, placebo controlled, randomized withdrawal period. [ Time Frame: 11 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 yrs old or older
  • moderate to severe pruritus
  • end stage renal disease
  • 3x weekly hemodialysis

Exclusion Criteria:

  • pruritus not due to renal disease
  • abnormal liver function
  • Ca-P > 80 mg/dl or HgB <8.5 g/dl or PTH > pg/mL
  • Within four months spKt/V < 1.05
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dawn McGuire, MD, Acologix, Inc Identifier: NCT00793156    
Other Study ID Numbers: AC120-8231
First Posted: November 19, 2008    Key Record Dates
Last Update Posted: February 4, 2010
Last Verified: February 2010
Keywords provided by Acologix, Inc.:
uremic pruritus
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases
Skin Manifestations